Morgan Stanley’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.2K | Sell |
4,567
-441
| -9% | -$4.66K | ﹤0.01% | 6631 |
|
|
2026
Q1 | $56.7K | Sell |
5,008
-816
| -14% | -$11.1K | ﹤0.01% | 6379 |
|
|
2025
Q4 | $74.5K | Buy |
5,824
+461
| +9% | +$7.09K | ﹤0.01% | 6304 |
|
|
2025
Q3 | $100K | Buy |
5,363
+92
| +2% | +$1.81K | ﹤0.01% | 6152 |
|
|
2025
Q2 | $135K | Sell |
5,271
-14
| -0.3% | -$281 | ﹤0.01% | 6020 |
|
|
2025
Q1 | $106K | Sell |
5,285
-46
| -0.9% | -$969 | ﹤0.01% | 5987 |
|
|
2024
Q4 | $97K | Sell |
5,331
-368
| -6% | -$7.22K | ﹤0.01% | 6072 |
|
|
2024
Q3 | $171K | Sell |
5,699
-12
| -0.2% | -$263 | ﹤0.01% | 5809 |
|
|
2024
Q2 | $80.3K | Sell |
5,711
-108
| -2% | -$1.87K | ﹤0.01% | 6040 |
|
|
2024
Q1 | $111K | Sell |
5,819
-180
| -3% | -$3.5K | ﹤0.01% | 5950 |
|
|
2023
Q4 | $133K | Sell |
5,999
-166
| -3% | -$4.93K | ﹤0.01% | 5836 |
|
|
2023
Q3 | $232K | Sell |
6,165
-10
| -0.2% | -$574 | ﹤0.01% | 5517 |
|
|
2023
Q2 | $443K | Sell |
6,175
-124
| -2% | -$7.84K | ﹤0.01% | 5280 |
|
|
2023
Q1 | $425K | Buy |
6,299
+732
| +13% | +$43.9K | ﹤0.01% | 5349 |
|
|
2022
Q4 | $173K | Buy |
5,567
+389
| +8% | +$11.5K | ﹤0.01% | 5728 |
|
|
2022
Q3 | $140K | Sell |
5,178
-10,278
| -66% | -$401K | ﹤0.01% | 5903 |
|
|
2022
Q2 | $677K | Buy |
15,456
+5,889
| +62% | +$270K | ﹤0.01% | 5259 |
|
|
2022
Q1 | $610K | Buy |
9,567
+660
| +7% | +$47.3K | ﹤0.01% | 5289 |
|
|
2021
Q4 | $745K | Sell |
8,907
-3,411
| -28% | -$383K | ﹤0.01% | 5286 |
|
|
2021
Q3 | $2M | Buy |
12,318
+512
| +4% | +$83.2K | ﹤0.01% | 4585 |
|
|
2021
Q2 | $1.78M | Buy |
11,806
+1,758
| +17% | +$296K | ﹤0.01% | 4721 |
|
|
2021
Q1 | $1.74M | Sell |
10,048
-281
| -3% | -$53.6K | ﹤0.01% | 4359 |
|
|
2020
Q4 | $1.65M | Buy |
10,329
+1,398
| +16% | +$234K | ﹤0.01% | 4315 |
|
|
2020
Q3 | $1.42M | Buy |
8,931
+373
| +4% | +$67.3K | ﹤0.01% | 3949 |
|
|
2020
Q2 | $1.7M | Sell |
8,558
-4,599
| -35% | -$845K | ﹤0.01% | 3749 |
|
|
2020
Q1 | $2.03M | Sell |
13,157
-5,887
| -31% | -$594K | ﹤0.01% | 3354 |
|
|
2019
Q4 | $1.47M | Buy |
19,044
+14,912
| +361% | +$1.3M | ﹤0.01% | 4266 |
|
|
2019
Q3 | $415K | Buy |
4,132
+2,229
| +117% | +$259K | ﹤0.01% | 4772 |
|
|
2019
Q2 | $252K | Sell |
1,903
-173
| -8% | -$23.8K | ﹤0.01% | 4926 |
|
|
2019
Q1 | $314K | Sell |
2,076
-1,558
| -43% | -$243K | ﹤0.01% | 4819 |
|
|
2018
Q4 | $587K | Sell |
3,634
-276
| -7% | -$54.8K | ﹤0.01% | 4685 |
|
|
2018
Q3 | $1.01M | Sell |
3,910
-384
| -9% | -$96.3K | ﹤0.01% | 4531 |
|
|
2018
Q2 | $979K | Buy |
4,294
+3,134
| +270% | +$593K | ﹤0.01% | 4646 |
|
|
2018
Q1 | $163K | Buy |
1,160
+757
| +188% | +$114K | ﹤0.01% | 5548 |
|
|
2017
Q4 | $52K | Buy |
403
+60
| +17% | +$7.63K | ﹤0.01% | 5829 |
|
|
2017
Q3 | $43K | Buy |
343
+218
| +174% | +$22.2K | ﹤0.01% | 5829 |
|
|
2017
Q2 | $11K | Sell |
125
-137
| -52% | -$12K | ﹤0.01% | 6212 |
|
|
2017
Q1 | $23K | Buy |
262
+204
| +352% | +$22.8K | ﹤0.01% | 6043 |
|
|
2016
Q4 | $6K | Sell |
58
-49
| -46% | -$5.37K | ﹤0.01% | 6250 |
|
|
2016
Q3 | $14K | Hold |
107
| – | – | ﹤0.01% | 6025 |
|
|
2016
Q2 | $10K | Sell |
107
-61
| -36% | -$5.31K | ﹤0.01% | 6058 |
|
|
2016
Q1 | $13K | Buy |
168
+48
| +40% | +$4.17K | ﹤0.01% | 6048 |
|
|
2015
Q4 | $13K | Sell |
120
-3
| -2% | -$409 | ﹤0.01% | 6174 |
|
|
2015
Q3 | $16K | Sell |
123
-5,706
| -98% | -$761K | ﹤0.01% | 6114 |
|
|
2015
Q2 | $715K | Buy |
5,829
+3,432
| +143% | +$467K | ﹤0.01% | 4448 |
|
|
2015
Q1 | $632K | Buy |
+2,397
| New | +$493K | ﹤0.01% | 4487 |
|
Other funds holding CTSO
AC
CM
SC
SIG
Morgan Stanley's CTSO Position: Q2 2026 in Review
Morgan Stanley reduced its Cytosorbents Corp (CTSO) stake by 8.8% in Q2 2026, selling an estimated $4.66K and leaving 4,567 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6631.
Morgan Stanley first reported a position in CTSO in Q1 2015 and has held it in 46 quarters since. The position peaked at $2.03M in Q1 2020. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Morgan Stanley held 4,567 shares of Cytosorbents Corp worth $34.2K as of Q2 2026.
- Morgan Stanley sold 441 Cytosorbents Corp shares in Q2 2026, an estimated $4.66K.
- Cytosorbents Corp made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6631 holding.
- Morgan Stanley first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 46 quarters since.
- Morgan Stanley's Cytosorbents Corp position peaked at $2.03M in Q1 2020.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.